Pediatric Brain Tumors Clinical Trials

Through clinical trials, our medical experts evaluate the safety and effectiveness of new therapies and diagnostic tools for brain tumors. Clinical trials can also help our doctors compare the effectiveness of different aspects of your child’s care, or determine the causes of brain tumors.

MSK has the most robust clinical research program in the tristate area for young people with brain tumors. We offer a wide range of clinical trials and are members of the Pediatric Brain Tumor Consortium, the Children’s Oncology Group, and the Neurofibromatosis Clinical Trials Consortium.

If your child is eligible to participate in a clinical trial, he or she may have access to new therapies that are not yet available elsewhere. Our clinical research team is highly experienced in selecting children who are most likely to benefit from a particular investigational therapy. They can guide you through the process of choosing the most appropriate clinical trial for your child’s needs.

Here you can find a list of many of Memorial Sloan Kettering’s current clinical trials for pediatric brain tumors. To learn more about a study, choose from the list below.

and/or
Reset
7 Clinical Trials found
A Phase 1 Study of Avutometinib, a Dual Inhibitor of MEK and RAF, for Children and Young Adults With Advanced Solid Tumors
Researchers want to find the best dose of avutometinib to treat children and young adults with advanced solid tumors. The people in this study have cancers that have spread or come back after treatment. In addition, their cancers have a mutation (change or variant) in a protein family called MAPK. These proteins tell cancer cells to grow.
New York City
A Phase 1/2 Study of CBL0137 to Treat Advanced Solid Tumors in Children and Young Adults
Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.
New York City
A Phase 2 Study of a Lower Radiation Therapy Dose to Treat Children and Young Adults With Central Nervous System Germinoma
Researchers are assessing a lower dose of standard radiation therapy after chemotherapy in young people with germinomas. The patients in this study have germinomas of the central nervous system (brain or spinal cord).  It is hoped that this new approach can destroy germinomas with fewer long-term side effects.
New York City
A Phase 2 Study of FORE8394 in People Who Have Cancer With BRAF Mutations
Researchers are seeing how well the drug FORE8394 works in people with advanced solid tumors, including brain tumors. The people in this study include adults and children with cancers that keep growing or came back even with treatment. Their tumors have mutations (changes or variants) in the BRAF gene.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase I/II Study of Alectinib in Children and Adolescents with Solid Tumors or Central Nervous System Tumors Containing a Change in the ALK Gene
The purpose of this study is to find the highest dose of the drug alectinib that can be given safely in children and adolescents with solid tumors or brain and spinal cord cancers that persist after treatment and have a genetic change called an ALK gene fusion. With this gene fusion, the ALK gene attaches to part of another gene.
New York City
A Phase I/II Study of Selinexor and Radiation Therapy for Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma and High-Grade Glioma
The purpose of this study is to find the best dose of the drug selinexor that can be given safely with radiation therapy in young patients newly diagnosed with pediatric diffuse intrinsic pontine glioma (DIPG) or high-grade glioma. Researchers will also determine the effectiveness of combining selinexor with radiation therapy (given for eight weeks) followed by selinexor therapy alone for two years.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase II Study of Chemotherapy Followed by Radiation Therapy for Children and Young Adults with Localized Non-Germinomatous Germ Cell Tumors of the Brain or Spinal Cord
Studies have shown that patients with newly diagnosed localized non-germinomatous germ cell tumors (NGGCT) of the brain or spinal cord whose disease responds well to chemotherapy before receiving radiation therapy are more likely to be free of the disease for a longer time than patients in whom chemotherapy is less effective.
New York City